Global Blood Therapeutics is a product-focused company building a pipeline of innovative, oral medicines to revolutionize the treatment of chronic blood-based diseases and genetic disorders for which there are currently no available cures and only extremely limited therapeutic options. The company's SHAPE Platform enables the discovery and development of oral, small molecule drugs that change the shapes of key blood proteins to modify their functions, enhance vital biological pathways and drive therapeutic benefits. Global Blood Therapeutics' approach combines the most advanced computational biology and protein-ligand modeling with medicinal chemistry and empiric screening capabilities focused on allosteric modulation, while leveraging its team's world-leading expertise in blood biology and proven success in drug discovery and development. Global Blood Therapeutics is a private company launched in 2012 by Third Rock Ventures with an experienced leadership team and renowned scientific founders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/14/12 | $40,700,000 | Series A |
Third Rock Ventures | undisclosed |
| 01/06/15 | $48,000,000 | Series B |
Deerfield Management Company, L.P. Perceptive Life Sciences RA Capital Sabby Capital Wellington Management Company | undisclosed |
